


Product Data Sheet

Cas No.:	86386-73-4	Cat. No:	PC12932
Product Name:	Fluconazole.		
Product synonym:	氟康唑;2-(2,4-二氟苯基)-1,3-双(1H-1,2,4-三唑-1-基)-2-丙醇;大扶康;麦道氟康;A-(2,4-二氟苯基)-A-(1H-1,2,4-三唑-1-基甲基)-1H-1,2,4-三唑-1-基乙醇;2-(2,4-二氟苯基)-1,3-双(1H-1,2,4-三氮唑-1-基)-2-丙醇;Fluconazole 氟康唑;zzstandard 品牌 氟康唑对照品;博柔霉素;氟康唑 EP标准品;氟康唑 Fluconazole;氟康唑 USP31;氟康唑 USP标准品;氟康唑 标准品;氟康唑的用途以及物理性状;氟康唑峰鉴别 EP标准品;氟康唑工厂;氟康唑杂质;氟康唑杂质对照品;氟康唑中间体;格列本脲;抗真菌药 氟康唑;赛庚啉;盐酸环苯扎林;A-(2,4-二氟苯基)-A-(1H-1,2,4-三唑-1-基甲基)-1H-1,2,4-三;氟康唑,大扶康,麦道氟康;福司氟康唑杂质A;福司氟康唑杂质1;氟康唑, 医药级,纯度:>99%;高纯度, 氟康唑原粉, 可小包装零售		
Chemical name:	Fluconazole.		
MF:	C13H12F2N6O	FW:	306.2708
Purity:	≥98%	Batch No.:	-
Storage:			
Structural formula:			
λmax:	-	Formulation:	-
Solubility :			
SMILES :	FC1C([H])=C(C([H])=C([H])C=1C(C([H])([H])N1C([H])=NC([H])=N1)(C([H])([H])N1C([H])=NC([H])=N1)O[H])F		
InChI Code:	-		
InChI Key:			
WARNING This product is not for human or veterinary use.			

Product Description

三唑抗真菌剂, Fluconazole是抗真菌化合物, 可用于表面和全身性的真菌感染。

生物活性	Fluconazole (UK-49858) is a triazole antifungal agent with excellent activities against a broad range of fungi, especially against <i>Candida albicans</i> . Fluconazole inhibits <i>C. albicans</i> and <i>Candida kefyr</i> with IC _{99s} range from 0.20 µg/mL to 0.39 µg/mL.
------	--

体外研究(In Vitro)	Fluconazole inhibits 4 species of<i>Aspergillus fumigatus</i> with the IC₅₀s of 23.9-43.5 µg/mL. Fluconazole (0.20 µg/mL) inhibits significantly the mycelial-phase growth and germ tube elongation of <i>C. albicans</i> in a medium supplemented with serum. Fluconazole is a triazole antifungal agent that has been available for the treatment of infections due to <i>Candida</i>, <i>Cryptococcus</i>. The MIC₉₀ is highest for <i>C. krusei</i> (MIC ≥ 64 µg/mL) and <i>C. glabrata</i> (MIC, 32 µg/mL) and is ≤2 µg/mL for <i>C. albicans</i> (0.5 µg/mL), <i>C. parapsilosis</i> (2 µg/mL), <i>C. tropicalis</i> (2 µg/mL), <i>C. lusitaniae</i> (2 µg/mL), and <i>C. kefyr</i> (0.5 µg/mL). Fluconazole (0.1-50.0 µg/mL) damages the fungal cells and reduces their viability. Medlife has not independently confirmed the accuracy of these methods. They are for reference only. Cell Viability Assay <table><tr><td>Cell Line:</td><td><i>C.albicans</i> yeast cells (strain ATCC 26310 and strain TW)</td></tr><tr><td>Concentration:</td><td>0.1, 0.5, 5.0, 50.0 µg/mL</td></tr><tr><td>Incubation Time:</td><td>24 hours</td></tr><tr><td>Result:</td><td>The MICs against both strains were 0.5 µg/mL.</td></tr></table>	Cell Line:	<i>C.albicans</i> yeast cells (strain ATCC 26310 and strain TW)	Concentration:	0.1, 0.5, 5.0, 50.0 µg/mL	Incubation Time:	24 hours	Result:	The MICs against both strains were 0.5 µg/mL.									
Cell Line:	<i>C.albicans</i> yeast cells (strain ATCC 26310 and strain TW)																	
Concentration:	0.1, 0.5, 5.0, 50.0 µg/mL																	
Incubation Time:	24 hours																	
Result:	The MICs against both strains were 0.5 µg/mL.																	
体内研究(In Vivo)	Fluconazole (0, 0.5, 1, 2.5, 5, 7.5, and 10 mg/kg; administered intraperitoneally (i.p.) as a single dose) results in a 50% reduction in fungal densities (ED50) of 4.87 mg/kg in a murine model of systemic candidiasis. Fluconazole exhibits terminal elimination half-life of 2.4 h) following i.p. administration.The terminal half-life does not change with the dose of fluconazole administered. Medlife has not independently confirmed the accuracy of these methods. They are for reference only. <table><tr><td>Animal Model:</td><td>Female NYLAR mice (weight, 18 to 20 g; infected intravenously with <i>C. albicans</i> blastoconidia)</td></tr><tr><td>Dosage:</td><td>5, 10, 15 and 20 mg/kg (Pharmacokinetic Analysis)</td></tr><tr><td>Administration:</td><td>Given i.p. as a single dose</td></tr><tr><td>Result:</td><td>T_{1/2}=2.4 h</td></tr></table>	Animal Model:	Female NYLAR mice (weight, 18 to 20 g; infected intravenously with <i>C. albicans</i> blastoconidia)	Dosage:	5, 10, 15 and 20 mg/kg (Pharmacokinetic Analysis)	Administration:	Given i.p. as a single dose	Result:	T _{1/2} =2.4 h									
Animal Model:	Female NYLAR mice (weight, 18 to 20 g; infected intravenously with <i>C. albicans</i> blastoconidia)																	
Dosage:	5, 10, 15 and 20 mg/kg (Pharmacokinetic Analysis)																	
Administration:	Given i.p. as a single dose																	
Result:	T _{1/2} =2.4 h																	
包装储存	<table><tr><td>Powder</td><td>-20°C</td><td>3 years</td></tr><tr><td></td><td>4°C</td><td>2 years</td></tr><tr><td>In solvent</td><td>-80°C</td><td>6 months</td></tr><tr><td></td><td>-20°C</td><td>1 month</td></tr></table>	Powder	-20°C	3 years		4°C	2 years	In solvent	-80°C	6 months		-20°C	1 month					
Powder	-20°C	3 years																
	4°C	2 years																
In solvent	-80°C	6 months																
	-20°C	1 month																
	体外研究: DMSO : ≥ 100 mg/mL (326.51 mM) H₂O : 2 mg/mL (6.53 mM; Need ultrasonic) * "≥" means soluble, but saturation unknown. <table><tr><td rowspan="4">配制储备溶液</td><td>溶剂体积 质量 浓度</td><td>1 mg</td><td>5 mg</td><td>10 mg</td></tr><tr><td>1 mM</td><td>3.2651 mL</td><td>16.3255 mL</td><td>32.6509 mL</td></tr><tr><td>5 mM</td><td>0.6530 mL</td><td>3.2651 mL</td><td>6.5302 mL</td></tr><tr><td>10 mM</td><td>0.3265 mL</td><td>1.6325 mL</td><td>3.2651 mL</td></tr></table> * 产品不同，其溶解度不同。建议根据产品选择合适的溶剂配制储备溶液；配成溶液后，建议分装保存，避免反复冻融造成的产品失效。 储备液的保存方式和期限：-80°C, 6 months; -20°C, 1 month。-80°C 储存时，建议在 6 个月内使用，-20°C 储存时，	配制储备溶液	溶剂体积 质量 浓度	1 mg	5 mg	10 mg	1 mM	3.2651 mL	16.3255 mL	32.6509 mL	5 mM	0.6530 mL	3.2651 mL	6.5302 mL	10 mM	0.3265 mL	1.6325 mL	3.2651 mL
配制储备溶液	溶剂体积 质量 浓度		1 mg	5 mg	10 mg													
	1 mM		3.2651 mL	16.3255 mL	32.6509 mL													
	5 mM		0.6530 mL	3.2651 mL	6.5302 mL													
	10 mM	0.3265 mL	1.6325 mL	3.2651 mL														

建议在 1 个月内使用。

体内研究:

建议根据您的[实验动物和给药方式](#)选择适当的溶解方案。以下溶解方案都建议先按照 **体外研究** 方式配制澄清的储备液，再依次添加助溶剂：

——为保证实验结果的可靠性，澄清的储备液可以根据储存条件，适当保存；体内实验的工作液，建议您现用现配，当天使用； 以下溶剂前显示的百分比是指该溶剂在您配制终溶液中的体积占比；如在配制过程中出现沉淀、析出现象，可以通过加热和/或超声的方式助溶

溶解度数据

1. 建议依照次序添加每种溶剂： 10% DMSO 40% PEG300 5% Tween-80 45% saline
Solubility: ≥ 2.5 mg/mL (8.16 mM); Clear solution

此方案可获得 ≥ 2.5 mg/mL (8.16 mM，饱和度未知) 的澄清溶液。

以 1 mL 工作液为例，取 100 μL 25.0 mg/mL 的澄清 DMSO 储备液加到 400 μL PEG300 中，混合均匀；向上述体系中加入50 μL Tween-80，混合均匀；然后继续加入 450 μL生理盐水定容至 1 mL。

将 0.9 g 氯化钠，完全溶解于 100 mL ddH₂O 中，得到澄清透明的生理盐水溶液

2. 建议依照次序添加每种溶剂： 10% DMSO 90% (20% SBE-β-CD in saline)
Solubility: ≥ 2.5 mg/mL (8.16 mM); Clear solution

此方案可获得 ≥ 2.5 mg/mL (8.16 mM，饱和度未知) 的澄清溶液。

以 1 mL 工作液为例，取 100 μL 25.0 mg/mL 的澄清 DMSO 储备液加到 900 μL 20% 的 SBE-β-CD 生理盐水中，混合均匀。

将 2 g 磺丁基醚 β-环糊精加入 5 mL 生理盐水中，再用生理盐水定容至 10 mL，完全溶解，澄清透明

3. 建议依照次序添加每种溶剂： 10% DMSO 90% corn oil
Solubility: ≥ 2.5 mg/mL (8.16 mM); Clear solution

此方案可获得 ≥ 2.5 mg/mL (8.16 mM，饱和度未知) 的澄清溶液，此方案不适用于实验周期在半个月以上的实验。

以 1 mL 工作液为例，取 100 μL 25.0 mg/mL 的澄清 DMSO 储备液加到 900 μL玉米油中，混合均匀。

4. 建议依照次序添加每种溶剂： PBS
Solubility: 2 mg/mL (6.53 mM); Clear solution; Need ultrasonic and warming and heat to 60°C

*